Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $10.40

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.40.

A number of research firms have weighed in on IRWD. StockNews.com lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, November 12th. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a "hold" rating in a report on Monday, September 9th. Finally, Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a "market perform" rating and a $5.00 price target for the company.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the business's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares of the company's stock, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC raised its stake in shares of Ironwood Pharmaceuticals by 44.4% in the second quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company's stock worth $50,856,000 after purchasing an additional 2,400,000 shares during the last quarter. Pacer Advisors Inc. raised its position in Ironwood Pharmaceuticals by 26.6% during the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company's stock worth $46,473,000 after buying an additional 2,372,183 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Ironwood Pharmaceuticals by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company's stock valued at $55,889,000 after acquiring an additional 1,472,097 shares during the period. Stonepine Capital Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 1,982.8% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company's stock valued at $4,120,000 after acquiring an additional 951,988 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock worth $40,870,000 after acquiring an additional 677,024 shares during the period.

Ironwood Pharmaceuticals Trading Up 1.1 %

Shares of Ironwood Pharmaceuticals stock traded up $0.05 during trading on Wednesday, hitting $4.43. 2,150,245 shares of the stock traded hands, compared to its average volume of 2,834,480. The stock's fifty day simple moving average is $4.01 and its 200 day simple moving average is $4.81. The firm has a market cap of $708.92 million, a P/E ratio of -147.67 and a beta of 0.41. Ironwood Pharmaceuticals has a 52-week low of $3.06 and a 52-week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $91.60 million for the quarter, compared to analysts' expectations of $91.22 million. During the same period last year, the business posted $0.12 EPS. The company's revenue for the quarter was down 19.4% on a year-over-year basis. As a group, equities analysts expect that Ironwood Pharmaceuticals will post 0.08 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.